{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/migraine/management/adults/","result":{"pageContext":{"chapter":{"id":"eb14162e-c87a-5ca7-8eda-4acb5c336298","slug":"adults","fullItemName":"Scenario: Adults","depth":2,"htmlHeader":"<!-- begin field 4a49b934-94c7-41cd-8e5b-6eb311cfd90f --><h2>Scenario: Migraine in adults</h2><!-- end field 4a49b934-94c7-41cd-8e5b-6eb311cfd90f -->","summary":"Covers the management of people aged 18 years and older with migraine.","htmlStringContent":"<!-- begin item 59a5b746-930f-47d1-a85e-8b363b084586 --><!-- begin field 3f7bf3e4-440e-485c-8388-acd900ab683a --><p>From age 18 years onwards.</p><!-- end field 3f7bf3e4-440e-485c-8388-acd900ab683a --><!-- end item 59a5b746-930f-47d1-a85e-8b363b084586 -->","topic":{"id":"b2a19577-fc3a-5b75-948b-7c86424dba8f","topicId":"8d5c9fe8-c317-4160-9aa5-50f3a0456472","topicName":"Migraine","slug":"migraine","lastRevised":"Last revised in October 2020","chapters":[{"id":"f5de766d-b899-5cb2-978f-7194e0cbeaf4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"57045461-bc73-53e8-9968-49ab778a037a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"32406f3a-91ba-5801-9ef0-87ad7d9b3133","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"52e6d993-e2b2-59c3-920f-27f34a7ec2eb","slug":"changes","fullItemName":"Changes"},{"id":"9560b149-423e-5bf5-8239-ae3f4bc97616","slug":"update","fullItemName":"Update"}]},{"id":"f6c897d2-fd52-5c54-a91b-1b366dced50e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"058608e6-7b11-54ed-9d12-69b94ea020cf","slug":"goals","fullItemName":"Goals"},{"id":"95d8aa4b-0bce-5da9-b56a-a612d637a001","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9b5443b-1c38-5f3c-be42-3e7fffa429e3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5644cb5-763c-596c-8c47-919fec89ce47","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"92308844-16f7-5eeb-9c0a-ad97a07896ec","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b97a29bb-bac7-5bc8-907c-210d887086f2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"986db6f6-7568-5e6e-8095-5ce116d22307","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b6d1719e-8f6a-509b-90d2-7d1f38e19b05","slug":"definition","fullItemName":"Definition"},{"id":"e35d9975-5859-5454-9539-fab1a8ca6a43","slug":"causes","fullItemName":"Causes"},{"id":"3d8350c0-8bc5-5793-a577-411bc703d36f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eea7fb2e-ce45-5fa7-9ff5-5399f8305dd7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"ad3ec7a1-a418-5232-b554-b202784e3f46","slug":"complications","fullItemName":"Complications"}]},{"id":"23b2a2ec-5694-51eb-97af-5e80f8d0b792","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"86e96919-af81-53dc-805a-36533fa27637","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"1b00b35a-f7c5-5dc3-bd7d-6e72a973af14","slug":"assessment","fullItemName":"Assessment"},{"id":"33c2a435-70da-50e9-b336-2d81b68f99c9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1ece6bbf-1986-5392-be1d-427e9603f26a","fullItemName":"Management","slug":"management","subChapters":[{"id":"eb14162e-c87a-5ca7-8eda-4acb5c336298","slug":"adults","fullItemName":"Scenario: Adults"},{"id":"3bced75d-3a79-536f-976d-875a40bf1a8d","slug":"young-people-aged-12-17-years","fullItemName":"Scenario: Young people aged 12-17 years"},{"id":"604f5c24-3920-5626-893b-9c27575decc6","slug":"pregnant-or-breastfeeding-women","fullItemName":"Scenario: Pregnant or breastfeeding women"}]},{"id":"8e2844f3-6843-5776-a5a1-59b0cabc5b93","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d1661673-77b9-587b-94ce-e5b6ff9de8c5","slug":"drugs-for-acute-migraine","fullItemName":"Drugs for acute migraine"},{"id":"b69cd3a2-8118-552d-ba35-c7db1a498617","slug":"drugs-for-the-prevention-of-migraine","fullItemName":"Drugs for the prevention of migraine"}]},{"id":"daf55050-4154-5b6d-b8ab-0f86775d1038","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0fbeb3e2-26df-5d63-a045-8af31aed07ef","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"88a22f7c-7eb4-5b57-a406-ab204723d6c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"596ed3f2-0ac4-5fd9-9046-b304311543ee","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4597510-7ec3-5f98-b5a5-3ef55cd51b5e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"79a12dcb-038c-5fd4-a311-648c3ee61102","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"41030681-d726-58c4-b509-29748e404597","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9a8a7e48-db76-50eb-a585-96fe1b4a5977","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1ece6bbf-1986-5392-be1d-427e9603f26a","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"cf7b1324-d2de-5491-9f3f-1c9eb87131d9","slug":"information-self-care-advice","fullItemName":"Information and self-care advice","depth":3,"htmlHeader":"<!-- begin field 5b89447b-22cd-4c33-b071-5a996952ceba --><h3>What information and self-care advice should I give to person with migraine?</h3><!-- end field 5b89447b-22cd-4c33-b071-5a996952ceba -->","summary":null,"htmlStringContent":"<!-- begin item d12183a9-dc2c-43f2-ae02-babdf45c1fd9 --><!-- begin field 7bd38960-c8e0-4594-8361-15c4c65b4711 --><ul><li>Explain the diagnosis and provide information on migraine.<ul><li>Patient information is available from:<ul><li>NHS A-Z — <a data-hyperlink-id=\"a011b82c-4fbd-4b73-94e4-aa2a00e3f4b3\" href=\"https://www.nhs.uk/conditions/Migraine/\" target=\"_blank\">Migraine</a>.</li><li>The Migraine Trust — <a data-hyperlink-id=\"94f23e29-24d5-4e47-9c27-aa2a00e3f4e5\" href=\"https://www.migrainetrust.org/\" target=\"_blank\">Migraine</a>.</li></ul></li></ul></li><li>Advise the person that:<ul><li>Keeping a headache diary can be helpful in identifying <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/background-information/causes/\">triggers</a> and monitoring the effectiveness of treatment.<ul><li>For further information on headache diaries, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/headache-assessment/\">Headache - assessment</a>.</li></ul></li><li>Avoidance of known triggers and lifestyle changes such as stress management, good sleep hygiene, adequate hydration, regular meals, exercise, and maintenance of a healthy weight can help.<ul><li>Co-morbidities (such as sleep apnoea, insomnia, depression and anxiety) which may exacerbate migraine should be optimally treated — for further information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>, <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>, <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/\">Insomnia</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a>.</li></ul></li><li>Medication overuse headache (MOH) is common in people with migraine and can be avoided by restriction of acute medication to a maximum of 2 days per week.<ul><li>MOH can occur with 15 or more days per month use of simple analgesics (such as aspirin, ibuprofen and paracetamol) or 10 or more days use per month of triptans or combination analgesics.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/headache-medication-overuse/\">Headache - medication overuse</a>.</li></ul></li></ul></li><li>Ensure that women who have migraine with aura are not using combined hormonal contraception, as this is contraindicated.<ul><li>For further information on contraceptive use and migraine, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li></ul><!-- end field 7bd38960-c8e0-4594-8361-15c4c65b4711 --><!-- end item d12183a9-dc2c-43f2-ae02-babdf45c1fd9 -->","subChapters":[{"id":"d0433282-ed21-5889-85b1-e3935282df7f","slug":"basis-for-recommendation-942","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f7c0d64b-8da3-48b0-9176-bdef05c465a6 --><h4>Basis for recommendation</h4><!-- end field f7c0d64b-8da3-48b0-9176-bdef05c465a6 -->","summary":null,"htmlStringContent":"<!-- begin item 942d64d9-a34c-4fd4-a0b4-8b8cc3a04900 --><!-- begin field e628efa7-03dc-4eed-87dc-30cf8198be23 --><p>The recommendations on what information and self-care advice should be given to people with migraine are based on clinical guidelines <em>Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">BASH, 2010</a>],<em> Headaches in over 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>], <em>Primary care management of headache in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] and <em>Pharmacological management of migraine</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>], the American Headache Society Position Statement on <em>Integrating New Migraine Treatments Into Clinical Practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Dodick, 2018</a>].</p><h5>Headache diary</h5><ul><li>Several national guidelines including those from the National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) recommend that headache diaries are kept to help determine migraine frequency and triggers; assess effectiveness and adverse effects associated with treatment; and allow the person to take an active role in management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ICHD, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li></ul><h5>Trigger avoidance</h5><ul><li>Expert opinion in clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">UKTIS, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Dodick, 2018</a>] recognises that triggers for migraine may not be easily identified but where possible avoidance of known triggers should form part of migraine management and can reduce attack frequency.</li></ul><h5>Medication overuse headache</h5><ul><li>The risk of medication overuse headache (MOH) in people with migraine is highlighted in several clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ICHD, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Dodick, 2018</a>].</li><li>The International Headache Society states that medication overuse headache may be a factor in up to 50% of people with chronic migraine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ICHD, 2018</a>].</li><li>The recommendation on limiting acute treatments to an average of 2 headache days per week is based on clinical guidance from SIGN [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] and the American Headache Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>].</li></ul><!-- end field e628efa7-03dc-4eed-87dc-30cf8198be23 --><!-- end item 942d64d9-a34c-4fd4-a0b4-8b8cc3a04900 -->","subChapters":[]}]},{"id":"fc8bf94a-aad3-5f8d-8c10-160c33e804cb","slug":"acute-treatment","fullItemName":"Acute treatment","depth":3,"htmlHeader":"<!-- begin field bda97321-72b0-4190-9a14-13a78c6a5ea1 --><h3>What acute treatment should I prescribe?</h3><!-- end field bda97321-72b0-4190-9a14-13a78c6a5ea1 -->","summary":null,"htmlStringContent":"<!-- begin item 91635e80-44b4-4770-8b93-542045c27e29 --><!-- begin field 8aeb4b77-21a3-493f-a0ae-3fa3de601ad4 --><ul><li>Depending on the severity of attacks, associated symptoms, contraindications and comorbidities:<ul><li>Offer simple analgesia such as:<ul><li>Ibuprofen (400 mg) — if ineffective, consider increasing to 600 mg <em>or</em></li><li>Aspirin (900 mg) <em>or</em></li><li>Paracetamol (1000 mg).</li></ul></li><li>Offer a triptan, alone or in combination with, paracetamol or an NSAID:<ul><li>Oral sumatriptan (50–100 mg) is first choice — other triptans should be offered if sumatriptan fails.</li><li>If vomiting restricts oral treatment, consider a non-oral formulation (such as intra-nasal or subcutaneous).</li></ul></li><li>Consider offering an anti-emetic (such as metoclopramide 10mg or prochlorperazine 10mg) in addition to other acute medication even in the absence of nausea and vomiting.<ul><li>Metoclopramide should not be used regularly due to the risk of extrapyramidal side effects.</li></ul></li></ul></li><li>Advise the person that:<ul><li>Acute medication should be taken early while pain is mild.</li><li>If they have aura, triptans should be taken at the start of the headache and <em>not </em>at the start of the aura (unless the aura and headache start simultaneously).</li></ul></li><li>Do NOT offer ergots or opioids.</li><li>Arrange follow up within 2–8 weeks.</li></ul><!-- end field 8aeb4b77-21a3-493f-a0ae-3fa3de601ad4 --><!-- end item 91635e80-44b4-4770-8b93-542045c27e29 -->","subChapters":[{"id":"fb809a96-853c-5fda-9911-31af31052c1d","slug":"basis-for-recommendation-b45","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 36f4453e-783f-4315-9216-ec4051d3931a --><h4>Basis for recommendation</h4><!-- end field 36f4453e-783f-4315-9216-ec4051d3931a -->","summary":null,"htmlStringContent":"<!-- begin item b4577d75-33c1-4482-806d-2b2e5af8daef --><!-- begin field 21625943-82b5-455a-a28f-12506db1aac3 --><p>The recommendations on drug treatment for acute migraine are based on the clinical guidelines <em>Headaches in over 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>], <em>Primary care management of headache in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] and <em>Pharmacological management of migraine</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>], the American Headache Society Position Statement on <em>Integrating New Migraine Treatments Into Clinical Practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Dodick, 2018</a>].</p><h5>Acute treatments</h5><ul><li>NICE guidance on the acute treatment of migraine recommends either combination therapy with an oral triptan and a non-steroidal anti-inflammatory (NSAID) or oral triptan and paracetamol; or monotherapy with an oral triptan, NSAID, aspirin (900 mg) or paracetamol for people who prefer to take only one drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>].<ul><li>The NICE recommendations are based on a network meta-analysis of a variety of oral and subcutaneous treatments and the expert opinion of the Guideline Development Group (GDG). Four separate analyses (n=19 studies) of 10 different interventions (five monotherapy and five different combinations of two agents) were included.</li><li>Combination therapy — the evidence from the network meta-analysis (based on low and very low quality direct comparison evidence) showed good evidence of efficacy of combination treatment with a triptan and either paracetamol or an NSAID versus singly administered treatments. The evidence suggested that a triptan and NSAID was a more effective combination than a triptan and paracetamol.</li><li>Monotherapy — moderate to very low quality evidence showed moderate efficacy for monotherapy with an oral triptan, NSAID, aspirin, or paracetamol. All evidence was from orally administered drugs and was for NSAIDs at a minimum dose of 400 mg, aspirin at a minimum dose of 900 mg, and paracetamol at 1000 mg.</li></ul></li><li>SIGN guidance recommends aspirin (900 mg), ibuprofen (400 mg, increased to 600 mg if 400 mg is ineffective), or triptans (sumatriptan 50–100 mg first-line) as treatment for acute migraine. Combination therapy using sumatriptan (50–85 mg) and naproxen (500 mg) can also be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].<ul><li>SIGN suggests that acute treatment can be stepped or stratified. For example, in stepped treatment high-dose aspirin or ibuprofen could be offered first and, if this fails over three headaches, treatment stepped up to a triptan. For stratified treatment high dose aspirin or ibuprofen might be used for a milder headache and a triptan for a more severe headache.</li><li>SIGN guidance notes that trials of triptans have focused on a population aged 18–65 years — there is no information on triptan use in the over 65s. Triptans are not licensed for use in the elderly.</li></ul></li><li>UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] and international clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>] highlight the importance of considering contraindications, severity of pain, associated symptoms and patient preference in choice of treatment for migraine.<ul><li>The American Headache Society advises that oral treatments should be started at a low dose and titrated slowly until an adequate response develops, maximum dose is reached, or adverse effects occur.</li></ul></li><li>The SIGN guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] incorporates a table listing calculated numbers needed to treat for acute migraine therapies for an outcome of pain free at two hours in patients with moderate to severe pain compared to placebo, including:</li></ul><table data-table-id=\"226192b6-4fce-429e-86dd-acce014c0950\"><thead><tr><th scope=\"col\"> </th><th scope=\"col\">Numbers needed to treat</th></tr></thead><tbody><tr><td colspan=\"2\"><strong>Simple analgesia</strong></td></tr><tr><td>Paracetamol 1000 mg</td><td>12</td></tr><tr><td>Aspirin 900 mg or 1000 mg</td><td>8.1</td></tr><tr><td>Ibuprofen 400 mg</td><td>7.2</td></tr><tr><td>Ibuprofen 200 mg</td><td>9.7</td></tr><tr><td colspan=\"2\"><strong>Oral triptans</strong></td></tr><tr><td>Sumatriptan 50 mg</td><td>6.1</td></tr><tr><td>Sumatriptan 100 mg</td><td>4.7</td></tr><tr><td>Zolmitriptan 5 mg</td><td>4.8</td></tr><tr><td>Zolmitriptan 2.5 mg</td><td>5.0</td></tr><tr><td colspan=\"2\"><strong>Nasal sprays</strong></td></tr><tr><td>Sumatriptan 20 mg</td><td>4.7</td></tr><tr><td>Zolmitriptan 5 mg</td><td>3.0</td></tr><tr><td colspan=\"2\"><strong>Subcutaneous injection</strong></td></tr><tr><td>Sumatriptan 6 mg</td><td>2.3</td></tr></tbody></table><h5>Choice of triptan</h5><ul><li>SIGN [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] recommend sumatriptan (50–100 mg) as first choice of triptan in acute migraine.</li><li>NICE [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>] recommend that treatment is started with the least expensive triptan first as the GDG considered the different triptans to be equally effective.</li><li>Several guidelines (including NICE and SIGN) recommend offering an alternative triptan if the initial triptan fails as response to individual triptans varies from person to person.</li></ul><h5>Adverse effects of acute medication</h5><p>UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] and International guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>] highlight the importance of considering contraindications and comorbidities before prescribing acute medications including triptans.</p><ul><li>Triptans are contraindicated in people with cardiovascular and cerebrovascular disease and not licensed for use in the elderly.</li></ul><h5>Anti-emetics</h5><p>UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] and international [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] guidance is in agreement that an anti-emetic (prochlorperazine 10 mg or metoclopramide 10 mg) can be considered in the treatment of headache in people with acute migraine.</p><ul><li>In the NICE guidance, the recommendation that anti-emetics (metoclopramide and prochlorperazine) be added is based on GDG informal consensus. Evidence that anti-emetics have an independent action on pain in migraine, regardless of whether the person has either nausea or vomiting is based on moderate, low and very low quality evidence.</li><li>Very low quality evidence from one study suggested paracetamol plus an anti-emetic was more effective than triptans in producing headache response (improvement to mild or no pain) at 2 hours and indirect evidence from non-oral administration of anti-emetics showed efficacy at producing freedom from pain at 2 and 24 hours (moderate to very low quality evidence).</li><li>The NICE GDG agreed that the risk of anti-emetic drugs triggering extra-pyramidal side effects is greatest in people under 20 years of age, but consider that the benefits justify the risks associated with their use in this group.</li><li>Following a review by the European Medicines Agency metoclopramide should not be taken for longer than 5 days due to well-known risks of neurological effects such as short-term extrapyramidal effects associated with metoclopramide [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">MHRA, 2014</a>].</li></ul><h5>Avoidance of ergots and opioids</h5><ul><li>The NICE recommendation against the use of ergots was based on very low quality evidence for oral, nasal, subcutaneous, and intravenous preparations of ergot derivatives, which favoured the use of triptans, because of the high risk of adverse events with ergots [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>].</li><li>Opioids are not recommended because of their potential for causing medication-overuse headache, the risk of dependence/abuse and the potential to exacerbate nausea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>].</li></ul><!-- end field 21625943-82b5-455a-a28f-12506db1aac3 --><!-- end item b4577d75-33c1-4482-806d-2b2e5af8daef -->","subChapters":[]}]},{"id":"0cbca97f-fa59-54aa-9403-eca5758ae6d0","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field 2d1506a7-7b11-47ef-91e4-be15fe3e0c85 --><h3>How should I follow up an adult with migraine?</h3><!-- end field 2d1506a7-7b11-47ef-91e4-be15fe3e0c85 -->","summary":null,"htmlStringContent":"<!-- begin item 2e55b88c-2ca4-4bce-944b-059cc5083642 --><!-- begin field b3284dea-7066-4118-b20a-7585d7a30b95 --><ul><li>Arrange follow up within 2–8 weeks of starting treatment. At review:<ul><li>Discuss frequency of attacks, effectiveness of treatment, adverse effects and lifestyle improvements.</li><li>If treatment has been effective, is being used appropriately and is well tolerated, continue it (with appropriate medication reviews).<ul><li>Advise the person to attend for review sooner if headache changes in nature or adverse effects develop.</li></ul></li><li>If previous acute treatment has proven ineffective:<ul><li>Reconfirm the diagnosis — consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/management/adults/#referral-criteria\">referral</a>.</li><li>Consider alternative triptans (oral, nasal or subcutaneous) or combination therapy with an oral triptan and an NSAID or an oral triptan and paracetamol, if not tried previously and no contraindications.</li><li>Consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/management/adults/#preventive-treatment\">preventative therapy</a>.</li></ul></li><li>Reiterate advice on avoidance of medication overuse headache.</li></ul></li></ul><!-- end field b3284dea-7066-4118-b20a-7585d7a30b95 --><!-- end item 2e55b88c-2ca4-4bce-944b-059cc5083642 -->","subChapters":[{"id":"39a67993-e1b2-55a6-afd8-82eaac9bde3c","slug":"basis-for-recommendation-8e5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fa95e2cf-5718-4de2-a19f-148fb5d6be70 --><h4>Basis for recommendation</h4><!-- end field fa95e2cf-5718-4de2-a19f-148fb5d6be70 -->","summary":null,"htmlStringContent":"<!-- begin item 8e5411ca-b1ad-462d-af45-4c2b9e8da9b2 --><!-- begin field e1307ea2-15f3-485a-94a8-dd44715e5d92 --><p>The recommendations on the follow up of migraine in adults are based on the clinical guidelines <em>Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">BASH, 2010</a>], <em>Headaches in over 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>], <em>Primary care management of headache in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] and <em>Pharmacological management of migraine</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>], a North American Guideline on <em>Diagnosis and treatment of headache </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ICSI, 2013</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Dodick, 2018</a>].</p><h5>Follow up</h5><ul><li>The Sottish Intercollegiate Guidelines Network (SIGN) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] and the Institute of Health Economics Alberta [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] recommend that people with migraine are fully assessed at follow-up visits to determine if their acute migraine medications need altered.</li></ul><p><strong>Possible reasons for a poor response to migraine treatment include</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ICSI, 2013</a>]<strong>:</strong></p><ul><li>Medication used too little or too late in the attack, or, conversely, used too much (medication overuse).</li><li>Inadequate medication for the degree of disability caused by migraine. The person may be using an unsuitable formulation (for example using an oral drug where vomiting is a symptom).</li><li>Failure to use adjunctive medication, such as analgesics or anti-emetics.</li><li>Inaccurate diagnosis.</li></ul><!-- end field e1307ea2-15f3-485a-94a8-dd44715e5d92 --><!-- end item 8e5411ca-b1ad-462d-af45-4c2b9e8da9b2 -->","subChapters":[]}]},{"id":"7a9073a5-77b9-5406-931c-a36a8d97fc52","slug":"preventive-treatment","fullItemName":"Preventive treatment","depth":3,"htmlHeader":"<!-- begin field 9b618107-b427-43db-b1ce-d0b25cf7c8a8 --><h3>Preventive treatment</h3><!-- end field 9b618107-b427-43db-b1ce-d0b25cf7c8a8 -->","summary":null,"htmlStringContent":"<!-- begin item 787592a5-d0c5-4a0f-b88c-cba54361a9c7 --><!-- begin field 18ea6834-6c89-4a7d-b6f4-4cbcc88a9772 --><ul><li>For information on:<ul><li>When to consider preventive treatment, see <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/management/adults/#criteria-for-preventive-treatment\">Criteria for preventive treatment</a>.</li><li>What treatments are recommended for migraine prevention and how to follow up a person on preventative treatment, see <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/management/adults/#choice-of-preventive-treatment\">Choice of preventative treatment and follow up</a>.</li><li>What treatments are recommended for prevention of menstrual or menstrual-related migraine, see <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/management/adults/#preventive-drugs-for-pure-menstrual-menstrually-related-migraine\">Preventive drugs for menstrual and menstrual-related migraine</a>.</li></ul></li></ul><!-- end field 18ea6834-6c89-4a7d-b6f4-4cbcc88a9772 --><!-- end item 787592a5-d0c5-4a0f-b88c-cba54361a9c7 -->","subChapters":[{"id":"a91a12f9-ba72-52ac-881a-21eb5d99aec9","slug":"criteria-for-preventive-treatment","fullItemName":"Criteria for preventive treatment","depth":4,"htmlHeader":"<!-- begin field 342e13aa-14ae-4792-b01b-9540bcf71935 --><h4>When should I consider preventive treatment?</h4><!-- end field 342e13aa-14ae-4792-b01b-9540bcf71935 -->","summary":null,"htmlStringContent":"<!-- begin item 5ae34974-c056-453f-8e39-f1ed2319c5fe --><!-- begin field 8bb8fb18-4b5f-45de-9f6e-978373a78b01 --><ul><li>The aim of preventive treatment is to reduce the frequency, severity, and duration of migraine attacks, and avoid medication-overuse headache.</li><li>Consider preventative treatment if:<ul><li>Migraine attacks are having a significant impact on quality of life and daily function, for example they occur frequently (more than once a week on average) or are prolonged and severe despite optimal acute treatment.</li><li>Acute treatments are either contraindicated or ineffective.</li><li>The person is at risk of medication overuse headache (MOH) due to frequent use of acute drugs.<ul><li>It is essential to rule out medication overuse headache (MOH) before preventive treatment is initiated.</li><li>If MOH is suspected then the appropriate management is drug withdrawal — see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/headache-medication-overuse/\">Headache - medication overuse</a> for further information.</li></ul></li></ul></li><li>If migraine is of an uncommon type (for example hemiplegic migraine, or migraine with prolonged aura) — <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/management/adults/#referral-criteria\">refer</a> or seek expert advice before considering preventative medication.</li></ul><!-- end field 8bb8fb18-4b5f-45de-9f6e-978373a78b01 --><!-- end item 5ae34974-c056-453f-8e39-f1ed2319c5fe -->","subChapters":[{"id":"f87c53c3-5b4a-5e33-b92d-41a28c4b0470","slug":"basis-for-recommendation-c92","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field b96b73c0-f583-4ff0-9f36-90067b148bcd --><h5>Basis for recommendation</h5><!-- end field b96b73c0-f583-4ff0-9f36-90067b148bcd -->","summary":null,"htmlStringContent":"<!-- begin item c92d57dd-9012-4e0b-9615-2c48e4b3cd6c --><!-- begin field ea920b03-10d9-4c13-b8c5-89cc311a769c --><p>The recommendations on when to consider preventative treatment are based on the clinical guidelines <em>Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">BASH, 2010</a>], <em>Headaches in over 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>], <em>Pharmacological management of migraine</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] and the American Headache Society Position Statement On <em>Integrating New Migraine Treatments Into Clinical Practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>] and expert opinion in narrative reviews [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Snow et al, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Pringsheim et al, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Fenstermacher et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>].</p><!-- end field ea920b03-10d9-4c13-b8c5-89cc311a769c --><!-- end item c92d57dd-9012-4e0b-9615-2c48e4b3cd6c -->","subChapters":[]}]},{"id":"43484b57-22d8-5ccd-a73b-24c8a7b20791","slug":"choice-of-preventive-treatment","fullItemName":"Choice of preventive treatment","depth":4,"htmlHeader":"<!-- begin field 8e6c32d8-7b13-4021-a6de-b2af4e5e9d2b --><h4>Which preventive treatment should I offer?</h4><!-- end field 8e6c32d8-7b13-4021-a6de-b2af4e5e9d2b -->","summary":null,"htmlStringContent":"<!-- begin item 60706c50-67b4-44a7-87a5-ead9a2adc795 --><!-- begin field f5155c66-bb74-4e62-83ce-9234ab7cd651 --><ul><li>Choice of preventative medication depends on contraindications, comorbidities, and risk of adverse events.<ul><li>Before prescribing, discuss the benefits (reduction in attacks) and risks (adverse effects) with the person as ultimately they should decide whether to try preventive treatment.</li><li>Some preventative therapies are contraindicated in pregnancy — potential harmful effects and the need for highly effective contraception must be discussed before starting treatment.</li><li>Drug treatment should be initiated at low dose and titrated according to efficacy and tolerability.</li></ul></li><li>Advise the person that:<ul><li>The aim of treatment is to reduce the frequency and severity of migraine symptoms and <em>not </em>complete remission or cure of migraine.</li><li>Acute treatment and avoidance of known <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/background-information/causes/\">triggers</a> and lifestyle modification will still be required.</li></ul></li><li>Consider pharmacological therapies such as:<ul><li>Propranolol (80–160 mg daily, in divided doses) or</li><li>Topiramate (50–100 mg daily, in divided doses [contraindicated in pregnancy — highly effective contraception is required prior to initiation]) or</li><li>Amitriptyline (25–75 mg at night).</li></ul></li><li>Do NOT offer gabapentin for migraine prophylaxis.</li><li>Consider non-pharmacological therapies as an adjunct or alternative to pharmacological therapy depending on the specific clinical situation and the person’s preference, including:<ul><li>Behavioural interventions (such as relaxation techniques [for example mindfulness or meditation] or cognitive behavioural therapy).</li><li>Acupuncture (up to 10 sessions over 5–8 weeks) if both topiramate and propranolol are unsuitable or ineffective.</li><li>Riboflavin 400 mg once a day — may be effective in reducing migraine frequency and intensity for some people (avoid if planning a pregnancy or pregnant).</li></ul></li><li>Arrange follow up to monitor effectiveness, titrate dose and assess for adverse effects.<ul><li>Review regularly during titration (for example every 2–3 weeks). Advise the person:<ul><li>To keep a headache diary.</li><li>To seek review sooner if adverse effects/new features develop.</li><li>That improvement may take 4–8 weeks from initiation of treatment to become apparent.</li></ul></li><li>Consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/management/adults/#referral-criteria\">referral</a> to neurology if prophylactic treatment in primary care fails, is not appropriate or any red flags or atypical clinical features develop.<ul><li>Treatment is considered to have failed if there is a lack of response to the highest tolerated dose after 3 months of treatment.</li></ul></li><li>After 6–12 months of successful therapy:<ul><li>Review the need for continuing migraine prophylaxis.</li><li>Consider gradual drug withdrawal.</li></ul></li></ul></li></ul><!-- end field f5155c66-bb74-4e62-83ce-9234ab7cd651 --><!-- end item 60706c50-67b4-44a7-87a5-ead9a2adc795 -->","subChapters":[{"id":"9e952ee0-2515-5fd5-ac97-6ff67851664a","slug":"basis-for-recommendation-59f","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field d0b793bd-8eee-4727-80bf-5c3df872ef4b --><h5>Basis for recommendation</h5><!-- end field d0b793bd-8eee-4727-80bf-5c3df872ef4b -->","summary":null,"htmlStringContent":"<!-- begin item 59f1ab0d-d495-401c-b6ff-150d2ebc9c33 --><!-- begin field e8c19df5-1cf2-46a6-afd2-d7581a4e4c7e --><p>The recommendations on preventative treatment for migraine are based on the clinical guidelines <em>Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication-overuse headache</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">BASH, 2010</a>], <em>Headaches in over 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>], <em>Primary care management of headache in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] and <em>Pharmacological management of migraine</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>], the American Headache Society Position Statement On <em>Integrating New Migraine Treatments Into Clinical Practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Dodick, 2018</a>].</p><h6>Realistic treatment expectations</h6><p>UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] and international guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] recommend discussing realistic treatment goals.</p><ul><li>A reduction in migraine headache severity and/or frequency of 30–50% is widely accepted as a successful outcome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li></ul><h6>Pharmacological therapy</h6><ul><li><strong>Propanolol</strong><ul><li>Propranolol is recommended by NICE and SIGN as a first-line prophylactic treatment for people with episodic or chronic migraine (if not contraindicated) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li><li>The likelihood of a 50% reduction in headache frequency in direct comparative trials (low quality) did not differ between propranolol and topiramate. Similarly, there was no difference when compared to amitriptyline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li></ul></li><li><strong>Topiramate</strong><ul><li>Topiramate is recommended by NICE and SIGN as a prophylactic treatment for people with episodic or chronic migraine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li><li>Use in Scotland is restricted to people who have not responded to at least one other prophylactic agent [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li><li>Guidance from NICE and SIGN and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>] highlight the risks of topiramate during pregnancy and recommend advising the woman of these, the need to use highly effective contraception (topiramate can impair the effectiveness of some hormonal contraceptives) and the need to seek further advice on migraine prophylaxis if pregnant or planning a pregnancy.</li></ul></li><li><strong>Amitriptyline</strong><ul><li>Low dose amitriptyline is recommended in UK ([<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>]) and Canadian [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] guidelines for the prophylactic treatment of migraine.</li><li>The dose range for amitriptyline (25-75 mg at night) is taken from the BNF.</li><li>SIGN guidance states that amitriptyline (25–150 mg at night) can be considered as a prophylactic treatment for patients with episodic or chronic migraine — target dose 30-50mg at night.</li><li>NICE guidance states that amitriptyline can be considered for the prophylactic treatment of migraine according to the person's preference, comorbidities and risk of adverse events – no dose range is specified.</li><li>The updated NICE evidence review (2015) found evidence comparing amitriptyline with topiramate, but not with placebo, and there was uncertainty about the effectiveness of amitriptyline as a prophylactic treatment.</li><li>Comparative trials of beta blockers and tricyclic antidepressants, amitriptyline and topiramate, and amitriptyline and flunarizine found no difference in likelihood of 50% reduction in headache attacks. Data is lacking [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li></ul></li></ul><h6>Do not prescribe gabapentin</h6><p>Guidance from NICE and SIGN ([<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] agrees that gabapentin should <em>not</em> be considered as a prophylactic treatment for migraine.</p><ul><li>Gabapentin is no better than placebo for prophylactic treatment of migraine in adults, is commonly associated with adverse events and increased risk of addiction.</li></ul><h6>Non-pharmacological therapies</h6><p>Non-pharmacological therapies can be used alone or in conjunction with pharmacological preventative medication and may be particularly useful where; drug treatment is contraindicated or poorly tolerated; there is a history of medication overuse headache; pregnancy is planned or during pregnancy or lactation; the person prefers to avoid drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Dodick, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>].</p><ul><li>Behavioural therapies — evidence suggests that therapies such as relaxation techniques, biofeedback, and cognitive behavioural therapy can be helpful for many people with migraine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Dodick, 2018</a>].</li><li>SIGN recommends encouraging relaxation techniques such as mindfulness, yoga or meditation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li><li>Acupuncture — NICE recommend considering a course of up to 10 sessions of acupuncture over 5–8 weeks according to the person's preference, comorbidities and risk of adverse events if both topiramate and propranolol are unsuitable or ineffective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>]. </li><li>Riboflavin — NICE recommend riboflavin (400 mg once a day) as it may be effective in reducing migraine frequency and intensity for some people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>].<ul><li>Riboflavin is also suggested as an option for migraine prophylaxis in Canadian guidelines — use if pregnant or planning a pregnancy should be avoided due to teratogenic risk at high dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>].</li><li>Riboflavin 400 mg per day is available as a food supplement and may be purchased over-the-counter.</li></ul></li></ul><h6>Follow up</h6><p>Careful follow up of all people on preventive migraine treatment is essential to monitor response and consider the possibility of discontinuing or tapering treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>].</p><ul><li>Migraine is cyclical, with periods of acute exacerbation followed by more benign periods, so prolonged administration of a preventive drug is rarely appropriate. The person should be reviewed and treatment reduced or stopped after about 6 months.</li><li>Guidance from NICE and SIGN recommend reviewing the ongoing need for prophylactic medication after six to 12 months — in many people it can be successfully phased out.</li><li>The American Headache Society advises caution in withdrawal of preventative medication in people with longstanding chronic migraine or where multiple preventative treatments have failed as migraine control may not be easily recaptured even if a previously effective treatment is restarted [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">American Headache Society, 2019</a>].</li></ul><!-- end field e8c19df5-1cf2-46a6-afd2-d7581a4e4c7e --><!-- end item 59f1ab0d-d495-401c-b6ff-150d2ebc9c33 -->","subChapters":[]}]},{"id":"d84ee395-c344-5e8b-b93f-ef5170d14d76","slug":"preventive-drugs-for-pure-menstrual-menstrually-related-migraine","fullItemName":"Preventive drugs for pure menstrual and menstrually-related migraine","depth":4,"htmlHeader":"<!-- begin field 20d1f9eb-fe1b-4704-95d2-f8baf40ab23e --><h4>Which preventive drug regimen should I prescribe for pure menstrual and menstrual-related migraine?</h4><!-- end field 20d1f9eb-fe1b-4704-95d2-f8baf40ab23e -->","summary":null,"htmlStringContent":"<!-- begin item 24dd36c7-7192-4a35-a175-6dc162998fae --><!-- begin field 1f4afc3a-ef9a-49aa-ba1c-c9331aefb565 --><ul><li>For women with predictable menstrual-related migraine that does not respond adequately to <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/management/adults/#information-self-care-advice\">lifestyle measures</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/management/adults/#acute-treatment\">standard acute treatment</a> and where there are no contraindications consider treatment (off-label) with:<ul><li>Frovatriptan (2.5 mg twice daily) on the days migraine is expected <em>or</em> from two days before until three days after bleeding starts.</li><li>Zolmitriptan (2.5 mg twice or three times daily) on the days migraine is expected <em>or</em> from two days before until three days after bleeding starts.</li></ul></li><li>Give advice on the risk of medication overuse headache.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/headache-medication-overuse/\">Headache - medication overuse</a>.</li></ul></li><li>Review contraceptive use:<ul><li>In migraine (especially migraine with aura) combined hormonal contraceptive use may increase the risk of vascular events and should be avoided.</li><li>For further information on contraceptive use and migraine, see CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li><li>Arrange follow up to monitor effectiveness and assess for adverse effects. <ul><li>Advise the person:<ul><li>To seek review sooner if adverse effects/new features develop.</li><li>To keep a headache diary.</li></ul></li><li>Consider the need for specialist advice/referral to neurology if prophylactic treatment in primary care fails, is not appropriate or any red flags or atypical clinical features develop.</li></ul></li></ul><!-- end field 1f4afc3a-ef9a-49aa-ba1c-c9331aefb565 --><!-- end item 24dd36c7-7192-4a35-a175-6dc162998fae -->","subChapters":[{"id":"d1e74921-17f2-56b7-9abb-62e2f8ee3007","slug":"basis-for-recommendation-784","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 339123c7-613e-41ca-9a48-48acc743864c --><h5>Basis for recommendation</h5><!-- end field 339123c7-613e-41ca-9a48-48acc743864c -->","summary":null,"htmlStringContent":"<!-- begin item 7840bf20-db9d-4cdd-a1b8-d3065137037d --><!-- begin field 37189434-7b2c-4d7a-b74f-7bd84fdb5ede --><p>The recommendations on treatment of menstrual-related migraine are based on the clinical guidelines <em>Headaches in over 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>], <em>Primary care management of headache in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] and <em>Pharmacological management of migraine</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</p><h6>Menstrual and menstrual-related migraine</h6><p>The drop in oestrogen before menstruation is a known trigger for migraine.</p><ul><li>In some women migraine only occurs (pure menstrual migraine) or predominantly occurs (menstrual-related migraine) from two days before the start of bleeding until three days after. If the menstrual cycle is regular and other treatments have failed in this group of women, perimenstrual strategies may be considered instead of standard preventative treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Maasumi, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li></ul><h6>Triptans for menstrual-related migraine</h6><ul><li>Guidance from the National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) recommend frovatriptan or zolmitriptan for the treatment of women with acute migraine associated with menstruation if other acute treatments have failed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>].</li><li>There is some variation in recommendations on the timing of migraine prophylaxis:<ul><li>NICE recommend that frovatriptan (2.5 mg twice a day) or zolmitriptan (2.5 mg twice or three times a day) are taken on the days migraine is expected.</li><li>SIGN recommend frovatriptan (2.5 mg twice daily) or zolmitriptan (2.5 mg twice or three times daily) are taken from two days before until three days after bleeding starts.</li></ul></li></ul><h6>Contraceptive use</h6><ul><li>It is widely accepted that combined oral contraceptive (COC) methods should be avoided in migraine due to increased risk of vascular events [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Sacco, 2017</a>].</li><li>A systematic review (n= 7 articles) looking at safety of hormonal contraceptives among women with migraine found limited evidence suggesting a two to fourfold increased risk of stroke among women with migraine who use COCs compared to those who did not [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Tepper, 2016</a>].</li></ul><!-- end field 37189434-7b2c-4d7a-b74f-7bd84fdb5ede --><!-- end item 7840bf20-db9d-4cdd-a1b8-d3065137037d -->","subChapters":[]}]}]},{"id":"7c8eb6e1-1891-5d29-810b-d65b5ae1cbc5","slug":"referral-criteria","fullItemName":"Referral criteria","depth":3,"htmlHeader":"<!-- begin field 94a64803-8ddd-4d9d-b0ba-a730007e0d6e --><h3>When should I refer a person with migraine?</h3><!-- end field 94a64803-8ddd-4d9d-b0ba-a730007e0d6e -->","summary":null,"htmlStringContent":"<!-- begin item 1651c646-2c45-46b3-9676-a730007e0e32 --><!-- begin field 86b144fe-b9fe-4ad1-896c-a730007e0d6e --><ul><li>Consider admission or urgent referral if:<ul><li>A serious cause of headache is suspected (see the section on excluding <a class=\"topic-reference external-reference\" href=\"/topics/headache-assessment/diagnosis/headache-diagnosis/#red-flags\">serious secondary causes</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/headache-assessment/\">Headache - assessment</a>).</li><li>The person is in severe, uncontrolled status migrainosus (migraine lasting for more than 72 hours).</li></ul></li><li>Seek advice/refer to neurology (with urgency depending on the clinical situation) if:<ul><li>A <a class=\"topic-reference internal-reference\" href=\"/topics/migraine/background-information/complications/\">complication</a> of migraine has developed.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/migraine/diagnosis/diagnosis/\">Atypical symptoms</a> (such as motor weakness or poor balance) are present.</li><li>The diagnosis is uncertain.</li><li>Optimal treatment in primary care does not adequately control the symptoms (medication overuse headache should be considered).</li></ul></li></ul><!-- end field 86b144fe-b9fe-4ad1-896c-a730007e0d6e --><!-- end item 1651c646-2c45-46b3-9676-a730007e0e32 -->","subChapters":[{"id":"def2660d-5637-5d57-94c1-3a6a83c2b0d1","slug":"basis-for-recommendation-d08","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d790fba0-a439-4db5-9e42-a730007e0d71 --><h4>Basis for recommendation</h4><!-- end field d790fba0-a439-4db5-9e42-a730007e0d71 -->","summary":null,"htmlStringContent":"<!-- begin item d08fed40-45f3-4b90-b267-a730007e0d71 --><!-- begin field 36d1c7ae-f8ba-4639-b6f1-a730007e0d71 --><p>The recommendations on when to refer a person with migraine are based on the clinical guidelines <em>Headaches in over 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>], <em>Primary care management of headache in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>] and <em>Pharmacological management of migraine</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>] and expert opinion in a consensus statement from the European Headache Federation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Martelletti, 2014</a>].</p><!-- end field 36d1c7ae-f8ba-4639-b6f1-a730007e0d71 --><!-- end item d08fed40-45f3-4b90-b267-a730007e0d71 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}